anti-FcRn monoclonal antibody SYNT001
Term · Oncology and biomedicine · MLC-T-ONC-010654
A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, SYNT001 targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, SYNT001 blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.
| Identifier | MLC-T-ONC-010654 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010654",
"term": "anti-FcRn monoclonal antibody SYNT001",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, SYNT001 targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, SYNT001 blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-fcrn-monoclonal-antibody-synt001/"
}
Record 1,754 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.